Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP1L1 gene therapy (InnoVec)
- Development stage
- Preclinical
- Lead developer
- Beijing InnoVec Biotherapeutics
- Modality
- Gene Therapies
- Administration
- Intravitreal
01
Overview
RP1L1 gene therapy (InnoVec) is an early-stage investigational adeno-associated virus (AAV) gene therapy being developed by Beijing Innovec Pharmaceutical Technology (InnoVec Biotherapeutics). The program is designed to treat inherited retinal diseases caused by mutations in the *RP1L1* gene, most notably occult macular dystrophy (OMD). The therapy utilizes an intravitreally delivered AAV vector to deliver a functional copy of the *RP1L1* gene to retinal cells, aiming to restore protein function and preserve vision. It is currently in the early discovery and preclinical stages of development.
- Other names
- RP1L1 gene therapyRP-1L1 gene therapyRP 1L1 gene therapyInnoVec RP1L1 program
02
Targets
RP1L1 (Retinitis pigmentosa 1-like 1 protein)
Beyond the preview
Go deeper on RP1L1 gene therapy (InnoVec).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP1L1 gene therapy (InnoVec).